Durvalumab: observed

79 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.

• Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07904494Report a problem
• GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)Not yet recruitingNCT07882212Report a problem
• Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)RecruitingNCT07855926Report a problem
• Real-world Insight Into Systemic Therapies for HCC: Single-center StudyRecruitingNCT07814014Report a problem
• A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLCNot yet recruitingNCT07760519Report a problem
• Molecular Characterization of Tumor-Microenvironment Interactions to Predict Drug Resistance in Gastric and GEJ AdenocarcinomaNot yet recruitingNCT07692477Report a problem
• MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.RecruitingNCT07607769Report a problem
• A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With PainRecruitingNCT07326137Report a problem
• Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in ChinaRecruitingNCT07161388Report a problem
• Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung CancerNot yet recruitingNCT07035860Report a problem
• Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing SurveillanceRecruitingNCT06995833Report a problem
• NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)RecruitingNCT06890273Report a problem
• Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid BiopsyRecruitingNCT06869239Report a problem
• Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular CarcinomaRecruitingNCT06806579Report a problem
• Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and DurvalumabRecruitingNCT06796114Not applicableReport a problem
• UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ AllianceRecruitingNCT06726720Report a problem
• Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)RecruitingNCT06717243Report a problem
• The Effect of Serum Ferritin in irAERecruitingNCT06702566Not applicableReport a problem
• Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC PatientsRecruitingNCT06634199Report a problem
• Imjudo & Imfinzi PMSRecruitingNCT06544629Report a problem
• NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic AlterationsRecruitingNCT06494540Report a problem
• Observational Study Protocol: LIVER-RRecruitingNCT06252753Report a problem
• A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.RecruitingNCT06205732Report a problem
• Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by ImmunotherapyRecruitingNCT05263830Report a problem
• Montreal Immune-Related Adverse Events (MIRAE) StudyRecruitingNCT05139706Report a problem
• A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint BlockadeRecruitingNCT04807127Report a problem
• Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC PatientsRecruitingNCT04680377Report a problem
• Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin ToxicityRecruitingNCT04631731Phase 1/2Report a problem
• JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint InhibitorsRecruitingNCT04294771Report a problem
• Microbiome Immunotherapy Toxicity and Response EvaluationRecruitingNCT04107168Report a problem
• Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.TerminatedNCT04381494Phase 4Results postedReport a problem
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02154490Results postedReport a problem
• Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and CanadaActive, not recruitingNCT07718139Report a problem
• Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in SohagActive, not recruitingNCT07669597Report a problem
• A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruitingNCT07645209Report a problem
• The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort StudyCompletedNCT07639294Report a problem
• Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRTCompletedNCT07309211Report a problem
• Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI StudyCompletedNCT07192926Report a problem
• Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)CompletedNCT07050472Report a problem
• REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCERCompletedNCT06826677Report a problem
• Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung CancerActive, not recruitingNCT06564870Report a problem
• An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With SurgeryActive, not recruitingNCT06117891Report a problem
• A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in BrazilActive, not recruitingNCT06008353Report a problem
• EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance DatabaseCompletedNCT05934214Report a problem
• RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in CanadaCompletedNCT05933044Report a problem
• Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompletedNCT05835778Report a problem
• Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompletedNCT05826366Report a problem
• Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T LymphocytesCompletedNCT05792995Phase 2Report a problem
• Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingNCT05761977Report a problem
• A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.Active, not recruitingNCT05683977Report a problem
• Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyCompletedNCT05667064Report a problem
• Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLCStatus unknownNCT05641870Report a problem
• A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in RussiaActive, not recruitingNCT05456867Report a problem
• Immunological Variables Associated to ICI Toxicity in Cancer PatientsStatus unknownNCT05429866Phase 2Report a problem
• Himalaya Early Access ProgramApproved for marketingNCT05345678Report a problem
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompletedNCT05332821Report a problem
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompletedNCT05332496Report a problem
• Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With DurvalumabStatus unknownNCT05027165Report a problem
• Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in BrazilCompletedNCT04948411Report a problem
• Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint InhibitorsCompletedNCT04898751Report a problem
• A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving DurvalumabCompletedNCT04884269Report a problem
• IMFINZI Study in Patients With Extensive Stage Small Cell Lung CancerCompletedNCT04854590Report a problem
• Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) ChemoradiotherapyActive, not recruitingNCT04711330Report a problem
• A Real-world Study of Durvalumab for Lung Cancer in ChinaStatus unknownNCT04672759Report a problem
• Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United KingdomCompletedNCT04667312Report a problem
• Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.Status unknownNCT04595734Report a problem
• Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)CompletedNCT04529564Report a problem
• Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II TrialActive, not recruitingNCT04432142Report a problem
• Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.Active, not recruitingNCT04364776Report a problem
• QUantitative Assessment of Swallowing After Radiation (QUASAR)Status unknownNCT04359199Report a problem
• Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 InhibitorsStatus unknownNCT04355806Report a problem
• Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.CompletedNCT04285866Report a problem
• Immune Related-adverse Events in Patients Receiving Immune Checkpoint InhibitorsStatus unknownNCT04268368Report a problem
• Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)CompletedNCT04068168Report a problem
• Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLCCompletedNCT03995875Report a problem
• First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After ChemoradiotherapyCompletedNCT03798535Report a problem
• IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation TherapyCompletedNCT03643484Report a problem
• Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReActionCompletedNCT03492242Report a problem
• Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse ReactionsCompletedNCT03387540Report a problem

← Durvalumab